Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Pipeline Review, H1 2018
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Pipeline Review, H1 2018
SUMMARY
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Histone deacetylase 1 is an enzyme encoded by the HDAC1 gene. The protein encoded by this gene belongs to the histone deacetylase family and is a component of the histone deacetylase complex. It also interacts with retinoblastoma tumor-suppressor protein and this complex is a key element in the control of cell proliferation and differentiation. Together with metastasis-associated protein-2 MTA2, it deacetylates p53 and modulates its effect on cell growth and apoptosis. It plays an important role in transcriptional regulation, cell cycle progression and developmental events.
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) pipeline Target constitutes close to 29 molecules. Out of which approximately 24 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 4, 6, 12 and 2 respectively.
Similarly, the universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Genetic Disorders, Hematological Disorders, Dermatology, Gastrointestinal, Immunology, Infectious Disease and Musculoskeletal Disorders which include indications Breast Cancer, Follicular Lymphoma, Non-Small Cell Lung Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Diffuse Large B-Cell Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Lung Cancer, Melanoma, Myelodysplastic Syndrome, Neuroblastoma, Relapsed Acute Myeloid Leukemia, Thalassemia, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), B-Cell Non-Hodgkin Lymphoma, Bile Duct Cancer (Cholangiocarcinoma), Colon Cancer, Cutaneous T-Cell Lymphoma, Essential Thrombocythemia, Liver Cancer, Mantle Cell Lymphoma, Metastatic Renal Cell Carcinoma, Mycosis Fungoides, Neurodegenerative Diseases, Non-Hodgkin Lymphoma, Pancreatic Cancer, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Prostate Cancer, Refractory Acute Myeloid Leukemia, Sickle Cell Disease, Solid Tumor, Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, Adenoid Cystic Carcinoma (ACC), Alopecia, Alzheimer's Disease, Anaplastic Thyroid Cancer, Basal Cell Carcinoma (Basal Cell Epithelioma), Becker Muscular Dystrophy, Bladder Cancer, Bone Disorders, Burkitt Lymphoma, Charcot-Marie-Tooth Disease Type II, Chronic Lymphocytic Leukemia (CLL), CNS Lymphoma, Colorectal Cancer, Depression, Duchenne Muscular Dystrophy, Endometrial Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Gallbladder Cancer, Glioblastoma Multiforme (GBM), Glioma, Gliosarcoma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Leiomyosarcoma, Liver Fibrosis, Lung Adenocarcinoma, Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Metastatic Uveal Melanoma, Multiple Myeloma (Kahler Disease), Myelofibrosis, Neuroendocrine Cancer, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Papillary Thyroid Cancer, Peripheral T-Cell Lymphomas (PTCL), Peritoneal Cancer, Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Psychiatric Disorders, Recurrent Glioblastoma Multiforme (GBM), Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Multiple Myeloma, Relapsed Chronic Lymphocytic Leukemia (CLL), Relapsed Multiple Myeloma, Renal Cell Carcinoma, Sezary Syndrome, Skin Cancer, Small-Cell Lung Cancer, Soft Tissue Sarcoma, Systemic Lupus Erythematosus and Thyroid Cancer.
The latest report Histone Deacetylase 1 - Pipeline Review, H1 2018, outlays comprehensive information on the Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Histone deacetylase 1 is an enzyme encoded by the HDAC1 gene. The protein encoded by this gene belongs to the histone deacetylase family and is a component of the histone deacetylase complex. It also interacts with retinoblastoma tumor-suppressor protein and this complex is a key element in the control of cell proliferation and differentiation. Together with metastasis-associated protein-2 MTA2, it deacetylates p53 and modulates its effect on cell growth and apoptosis. It plays an important role in transcriptional regulation, cell cycle progression and developmental events.
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) pipeline Target constitutes close to 29 molecules. Out of which approximately 24 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 4, 6, 12 and 2 respectively.
Similarly, the universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Genetic Disorders, Hematological Disorders, Dermatology, Gastrointestinal, Immunology, Infectious Disease and Musculoskeletal Disorders which include indications Breast Cancer, Follicular Lymphoma, Non-Small Cell Lung Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Diffuse Large B-Cell Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Lung Cancer, Melanoma, Myelodysplastic Syndrome, Neuroblastoma, Relapsed Acute Myeloid Leukemia, Thalassemia, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), B-Cell Non-Hodgkin Lymphoma, Bile Duct Cancer (Cholangiocarcinoma), Colon Cancer, Cutaneous T-Cell Lymphoma, Essential Thrombocythemia, Liver Cancer, Mantle Cell Lymphoma, Metastatic Renal Cell Carcinoma, Mycosis Fungoides, Neurodegenerative Diseases, Non-Hodgkin Lymphoma, Pancreatic Cancer, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Prostate Cancer, Refractory Acute Myeloid Leukemia, Sickle Cell Disease, Solid Tumor, Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, Adenoid Cystic Carcinoma (ACC), Alopecia, Alzheimer's Disease, Anaplastic Thyroid Cancer, Basal Cell Carcinoma (Basal Cell Epithelioma), Becker Muscular Dystrophy, Bladder Cancer, Bone Disorders, Burkitt Lymphoma, Charcot-Marie-Tooth Disease Type II, Chronic Lymphocytic Leukemia (CLL), CNS Lymphoma, Colorectal Cancer, Depression, Duchenne Muscular Dystrophy, Endometrial Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Gallbladder Cancer, Glioblastoma Multiforme (GBM), Glioma, Gliosarcoma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Leiomyosarcoma, Liver Fibrosis, Lung Adenocarcinoma, Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Metastatic Uveal Melanoma, Multiple Myeloma (Kahler Disease), Myelofibrosis, Neuroendocrine Cancer, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Papillary Thyroid Cancer, Peripheral T-Cell Lymphomas (PTCL), Peritoneal Cancer, Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Psychiatric Disorders, Recurrent Glioblastoma Multiforme (GBM), Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Multiple Myeloma, Relapsed Chronic Lymphocytic Leukemia (CLL), Relapsed Multiple Myeloma, Renal Cell Carcinoma, Sezary Syndrome, Skin Cancer, Small-Cell Lung Cancer, Soft Tissue Sarcoma, Systemic Lupus Erythematosus and Thyroid Cancer.
The latest report Histone Deacetylase 1 - Pipeline Review, H1 2018, outlays comprehensive information on the Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98)
- The report reviews Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects
- The report assesses Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope
Introduction
Global Markets Direct Report Coverage
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Overview
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Companies Involved in Therapeutics Development
4SC AG
AlfaSigma SpA
Celgene Corp
Chipscreen Biosciences Ltd
Curis Inc
HitGen LTD
IRBM Science Park SpA
Italfarmaco SpA
Medivir AB
MEI Pharma Inc
Merck & Co Inc
Mirati Therapeutics Inc
Syndax Pharmaceuticals Inc
Zhejiang Hisun Pharmaceutical Co Ltd
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Drug Profiles
4SC-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACY-1035 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACY-1071 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACY-738 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACY-957 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
crocetin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CS-3158 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
entinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fimepinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
givinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HG-3001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
largazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mocetinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pracinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RCY-1305 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RCY-1497 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RCY-1992 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
remetinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
resminostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Histone Deacetylase 1 for Beta Thalassemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit KDM1A, HDAC1 and HDAC2 for Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit BRD4 and HDAC1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit HDAC1 and 2 for Acute Myeloid Leukemia and Myelodysplastic Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit HDAC1, HDAC2 and HDAC3 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-3595 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit HDAC for Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tucidinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vorinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Dormant Products
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Discontinued Products
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Product Development Milestones
Featured News & Press Releases
Feb 07, 2018: University of Colorado: Treatment for Diastolic Dysfunction
Jan 31, 2018: Positive DSMB safety review of 4SC's pivotal RESMAIN study of resminostat in CTCL
Jan 11, 2018: Helsinn Group and MEI Pharma Announce that Pracinostat has Received Orphan Drug Designation from the European Medicines Agency for the Treatment of acute myeloid leukemia (AML)
Jan 10, 2018: Syndax Pharmaceuticals Announces Clinical Collaboration to Evaluate Entinostat in Combination with anti-PD-L1 Cancer Immunotherapy in Breast Cancer
Dec 20, 2017: 4SC receives Pediatric Investigation Plan Waiver for resminostat in CTCL from the European Medicines Agency
Dec 13, 2017: 4SC receives milestone payment from Immunic
Dec 11, 2017: Italfarmaco Presents Positive Phase II Study Results for Givinostat in Polycythemia Vera Patients at the ASH Annual Meeting
Dec 05, 2017: Italfarmaco Announces Givinostat Clinical Trial Presentations at the 59th American Society of Hematology (ASH) Annual Meeting
Dec 01, 2017: Curis Announces Upcoming Presentation at the American Society of Hematology 59th Annual Meeting & Exposition
Nov 11, 2017: Syndax Announces Presentation of ENCORE 601 Data at Society for Immunotherapy of Cancer 32nd Annual Scientific Meeting
Nov 07, 2017: Syndax to Present Data On Entinostat at SITC 32nd Annual Scientific Meeting
Oct 13, 2017: Remetinostat Phase II Data Demonstrate Efficacy on Skin Lesions, Reduction of Itching and High Tolerability in Patients With Early-stage MF-type CTCL
Oct 12, 2017: Mirati Therapeutics' Mocetinostat Included In Stand Up To Cancer's Cutting-Edge Clinical Trial Initiative For NSCLC Patients
Oct 10, 2017: Resminostat demonstrates potential to significantly alleviate itching in CTCL patients
Oct 05, 2017: Syndax Announces Dosing of First Patient in Pivotal Trial of Entinostat for the Treatment of Advanced or Recurrent Breast Cancer in Japan by Partner Kyowa Hakko Kirin
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Overview
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Companies Involved in Therapeutics Development
4SC AG
AlfaSigma SpA
Celgene Corp
Chipscreen Biosciences Ltd
Curis Inc
HitGen LTD
IRBM Science Park SpA
Italfarmaco SpA
Medivir AB
MEI Pharma Inc
Merck & Co Inc
Mirati Therapeutics Inc
Syndax Pharmaceuticals Inc
Zhejiang Hisun Pharmaceutical Co Ltd
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Drug Profiles
4SC-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACY-1035 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACY-1071 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACY-738 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACY-957 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
crocetin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CS-3158 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
entinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fimepinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
givinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HG-3001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
largazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mocetinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pracinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RCY-1305 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RCY-1497 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RCY-1992 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
remetinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
resminostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Histone Deacetylase 1 for Beta Thalassemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit KDM1A, HDAC1 and HDAC2 for Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit BRD4 and HDAC1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit HDAC1 and 2 for Acute Myeloid Leukemia and Myelodysplastic Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit HDAC1, HDAC2 and HDAC3 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-3595 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit HDAC for Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tucidinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vorinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Dormant Products
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Discontinued Products
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Product Development Milestones
Featured News & Press Releases
Feb 07, 2018: University of Colorado: Treatment for Diastolic Dysfunction
Jan 31, 2018: Positive DSMB safety review of 4SC's pivotal RESMAIN study of resminostat in CTCL
Jan 11, 2018: Helsinn Group and MEI Pharma Announce that Pracinostat has Received Orphan Drug Designation from the European Medicines Agency for the Treatment of acute myeloid leukemia (AML)
Jan 10, 2018: Syndax Pharmaceuticals Announces Clinical Collaboration to Evaluate Entinostat in Combination with anti-PD-L1 Cancer Immunotherapy in Breast Cancer
Dec 20, 2017: 4SC receives Pediatric Investigation Plan Waiver for resminostat in CTCL from the European Medicines Agency
Dec 13, 2017: 4SC receives milestone payment from Immunic
Dec 11, 2017: Italfarmaco Presents Positive Phase II Study Results for Givinostat in Polycythemia Vera Patients at the ASH Annual Meeting
Dec 05, 2017: Italfarmaco Announces Givinostat Clinical Trial Presentations at the 59th American Society of Hematology (ASH) Annual Meeting
Dec 01, 2017: Curis Announces Upcoming Presentation at the American Society of Hematology 59th Annual Meeting & Exposition
Nov 11, 2017: Syndax Announces Presentation of ENCORE 601 Data at Society for Immunotherapy of Cancer 32nd Annual Scientific Meeting
Nov 07, 2017: Syndax to Present Data On Entinostat at SITC 32nd Annual Scientific Meeting
Oct 13, 2017: Remetinostat Phase II Data Demonstrate Efficacy on Skin Lesions, Reduction of Itching and High Tolerability in Patients With Early-stage MF-type CTCL
Oct 12, 2017: Mirati Therapeutics' Mocetinostat Included In Stand Up To Cancer's Cutting-Edge Clinical Trial Initiative For NSCLC Patients
Oct 10, 2017: Resminostat demonstrates potential to significantly alleviate itching in CTCL patients
Oct 05, 2017: Syndax Announces Dosing of First Patient in Pivotal Trial of Entinostat for the Treatment of Advanced or Recurrent Breast Cancer in Japan by Partner Kyowa Hakko Kirin
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..3), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..4), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Products under Development by Companies, H1 2018 (Contd..5), H1 2018
Products under Development by Companies, H1 2018 (Contd..6), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by 4SC AG, H1 2018
Pipeline by AlfaSigma SpA, H1 2018
Pipeline by Celgene Corp, H1 2018
Pipeline by Chipscreen Biosciences Ltd, H1 2018
Pipeline by Curis Inc, H1 2018
Pipeline by HitGen LTD, H1 2018
Pipeline by IRBM Science Park SpA, H1 2018
Pipeline by Italfarmaco SpA, H1 2018
Pipeline by Medivir AB, H1 2018
Pipeline by MEI Pharma Inc, H1 2018
Pipeline by Merck & Co Inc, H1 2018
Pipeline by Mirati Therapeutics Inc, H1 2018
Pipeline by Syndax Pharmaceuticals Inc, H1 2018
Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd..1), H1 2018
Dormant Products, H1 2018 (Contd..2), H1 2018
Dormant Products, H1 2018 (Contd..3), H1 2018
Discontinued Products, H1 2018
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..3), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..4), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Products under Development by Companies, H1 2018 (Contd..5), H1 2018
Products under Development by Companies, H1 2018 (Contd..6), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by 4SC AG, H1 2018
Pipeline by AlfaSigma SpA, H1 2018
Pipeline by Celgene Corp, H1 2018
Pipeline by Chipscreen Biosciences Ltd, H1 2018
Pipeline by Curis Inc, H1 2018
Pipeline by HitGen LTD, H1 2018
Pipeline by IRBM Science Park SpA, H1 2018
Pipeline by Italfarmaco SpA, H1 2018
Pipeline by Medivir AB, H1 2018
Pipeline by MEI Pharma Inc, H1 2018
Pipeline by Merck & Co Inc, H1 2018
Pipeline by Mirati Therapeutics Inc, H1 2018
Pipeline by Syndax Pharmaceuticals Inc, H1 2018
Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd..1), H1 2018
Dormant Products, H1 2018 (Contd..2), H1 2018
Dormant Products, H1 2018 (Contd..3), H1 2018
Discontinued Products, H1 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
4SC AG
AlfaSigma SpA
Celgene Corp
Chipscreen Biosciences Ltd
Curis Inc
HitGen LTD
IRBM Science Park SpA
Italfarmaco SpA
Medivir AB
MEI Pharma Inc
Merck & Co Inc
Mirati Therapeutics Inc
Syndax Pharmaceuticals Inc
Zhejiang Hisun Pharmaceutical Co Ltd
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
4SC AG
AlfaSigma SpA
Celgene Corp
Chipscreen Biosciences Ltd
Curis Inc
HitGen LTD
IRBM Science Park SpA
Italfarmaco SpA
Medivir AB
MEI Pharma Inc
Merck & Co Inc
Mirati Therapeutics Inc
Syndax Pharmaceuticals Inc
Zhejiang Hisun Pharmaceutical Co Ltd
